Compare PTCT & BCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | BCPC |
|---|---|---|
| Founded | 1998 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.6B |
| IPO Year | 2006 | 1995 |
| Metric | PTCT | BCPC |
|---|---|---|
| Price | $82.28 | $168.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 2 |
| Target Price | $80.65 | ★ $176.00 |
| AVG Volume (30 Days) | ★ 2.2M | 211.0K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.55% |
| EPS Growth | ★ 264.48 | 20.87 |
| EPS | N/A | ★ 1.25 |
| Revenue | $264,734,000.00 | ★ $799,023,000.00 |
| Revenue This Year | N/A | $8.47 |
| Revenue Next Year | $17.70 | $4.89 |
| P/E Ratio | ★ N/A | $135.04 |
| Revenue Growth | ★ 36.19 | 13.56 |
| 52 Week Low | $43.18 | $139.17 |
| 52 Week High | $87.50 | $183.90 |
| Indicator | PTCT | BCPC |
|---|---|---|
| Relative Strength Index (RSI) | 65.15 | 61.58 |
| Support Level | $73.41 | $167.19 |
| Resistance Level | $87.27 | $169.74 |
| Average True Range (ATR) | 3.11 | 3.55 |
| MACD | 0.22 | 0.50 |
| Stochastic Oscillator | 75.57 | 55.92 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.